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Abstract
Background Behaviours such as agitation impact on the quality of life of care-home residents with dementia and increase 
healthcare use. Interventions to prevent these behaviours have little evidence supporting their effectiveness or cost-effec-
tiveness. We conducted an economic evaluation alongside a trial assessing Dementia Care Mapping™ (DCM) versus usual 
care for reducing agitation, and highlight methodological challenges of conducting evaluations in this population and setting.
Methods RCT data over 16 months from English care-home residents with dementia (intervention n = 418; control n = 308) 
were analysed. We conducted a cost-utility analysis from the healthcare provider perspective. We gathered resource use and 
utility (EQ-5D-5L and DEMQoL-Proxy-U) from people living with dementia and proxy informants (staff and relatives). 
Data were analysed using seemingly unrelated regression, accounting for care-home clustering and bootstrapping used to 
capture sampling uncertainty.
Results Costs were higher in the intervention arm than in the control arm (incremental = £1479) due in part to high cost 
outliers. There were small QALY gains (incremental = 0.024) in favour of DCM. The base-case ICER (£64,380 per QALY) 
suggests DCM is not cost-effective versus usual care. With the exception of analyses excluding high cost outliers, which 
suggested a potential for DCM to be cost-effective, sensitivity analyses corroborated the base-case findings. Bootstrapped 
estimates suggested DCM had a low probability (< 0.20 where λ = £20,000) of being cost-effective versus control.
Conclusion DCM does not appear to be a cost-effective intervention versus usual care in this group and setting. The evalua-
tion highlighted several methodological challenges relating to validity of utility assessments, loss to follow-up and compli-
ance. Further research is needed on handling high-cost individuals and capturing utility in this group.
ISRCTN reference 82288852.
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Key Points for Decision Makers 
Dementia Care Mapping is not cost-effective versus 
usual care in preventing or supporting agitation in care-
home residents with dementia.
The trial highlighted a number of challenges to the 
economic evaluation that future studies should consider 
at design stage including dealing with: low intervention 
compliance; high levels of missing data; uncertain valid-
ity of utility assessments in this population; and high 
cost outliers.
1 Introduction
It is estimated that over 35 million people have dementia 
worldwide and this figure is expected to increase [1–3]. 
While dementia disease course and outcomes vary across 
individuals, the condition usually has a significant impact 
on survival, functioning and quality of life. In addition, the 
societal costs of dementia, including costs to the healthcare 
system and the family costs of caring for those with the con-
dition, are considerable. These are estimated to be over £26 
billion per annum in the UK and projected to rise to £40 
billion per annum by 2040 [3].
Currently there is no cure for dementia, and therefore 
interventions aim to slow cognitive decline [4] and improve 
quality of life [5]. A significant challenge in supporting peo-
ple with dementia is the occurrence of behaviours that are 
termed ‘neuropsychiatric’ or ‘behavioural and psychologi-
cal’. These behaviours include agitation, shouting, biting, 
aggression, depression, anxiety and delusions, and can lead 
to harm of the person and others around them, caregiver 
stress and additional healthcare resource use [6]. As many 
as 90% of people living with dementia experience one or 
more of these behaviours at some point [7]. Over a third of 
people with dementia live in care homes and close to 80% of 
residents experience such behaviours at some point [8], with 
agitation being the most common [8] and having a signifi-
cant impact on resident quality of life [9] and care costs [4].
The occurrence of such behaviours is partly dependent 
on the ability of staff to provide person-centred care that 
meets residents’—often complex—individual needs [10]. 
Pharmacological treatments have limited efficacy and seri-
ous potential side effects including increased mortality, and 
thus psychosocial interventions are the recommended first 
line of treatment [11]. Psychosocial interventions can target 
the resident, caregiver or the care-home environment [12]. 
Dementia Care Mapping™ (DCM™) [13] is a care-home-
level intervention that aims to support the embedding of 
person-centred care, improve the quality of care and, con-
sequently, health outcomes for residents. It has been used 
widely in the UK and elsewhere [14, 15]. The DCM process 
involves provision of formal training to care-home staff to 
use the tool and a recurring five-phase implementation cycle 
of: briefing, observation, data analysis and reporting, feed-
back and action planning. Trained mappers conduct system-
atic observation of residents (behaviour, activities, mood, 
and quality of staff interactions and care approaches) and 
information is fed back to other staff involved in care to help 
with the implementation of person-centred care-action plans. 
This process is repeated every 4–6 months.
Despite widespread use of DCM, there is limited robust 
evidence of its effectiveness, and that provided by ran-
domised and non-randomised studies is mixed [16]. Evi-
dence on the value for money of DCM is scarcer still [17]. 
Only two studies report an economic evaluation of the 
intervention [4, 18], neither of which present cost-utility 
analyses.
Given that there are 16,000 care homes in England alone 
(mostly providing elderly care) [19] and growing numbers 
of people living with dementia, interventions in this con-
text and population, even if relatively cheap or infrequently 
adopted, have the potential to generate substantial oppor-
tunity costs. Hence, such interventions should be evalu-
ated thoroughly to establish value for money before full 
implementation.
The DCM EPIC trial was a pragmatic, cluster-ran-
domised, controlled trial of usual care plus DCM (interven-
tion) versus usual care (control) for reducing agitation in 
care-home residents with dementia [20]. The aim of the cur-
rent research was to conduct a full economic evaluation of 
the DCM-EPIC trial from a health- and social-care-provider 
perspective and over a 16-month time horizon, incorporating 
comprehensive costing, cost-effectiveness and cost-utility 
analyses. Furthermore, we wished to highlight methodologi-
cal issues we encountered in conducting an evaluation in this 
population and setting.
2  Methods
2.1  Trial
The DCM EPIC trial was conducted in England with care 
homes randomised 3:2 to intervention:control. Care homes 
and then individual residents were recruited into the study. 
Inclusion criteria for individuals included being a permanent 
care-home resident and having a formal diagnosis of demen-
tia. The primary outcome was agitation as measured on the 
Cohen-Mansfield Agitation Inventory (CMAI), a 29-item 
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measure assessing frequency of agitated or aggressive 
behaviour in the past 2 weeks [21]. The CMAI was com-
pleted by a staff member who knew the resident well. Data 
were gathered on health outcomes and dementia severity 
(Functional Assessment Staging Test (FAST) [22] and Clini-
cal Dementia Rating (CDR) [23]). Usual care was defined 
as care routinely delivered within the setting, and was likely 
to include person-centred care but excluded DCM training. 
DCM adhered to procedures outlined in the DCM manual 
and guidance [13, 24]. In brief, two staff members from each 
home were trained to use DCM (mappers) and then aimed 
to implement three DCM cycles with an expert mapper sup-
porting completion of the first cycle. DCM data were used 
to create action plans for improvements in the care home 
with progress on these actions monitored. Due to higher than 
expected resident loss to follow-up (approximately 50%), 
additional residents were recruited at 16 months to allow a 
cross-sectional analysis (open cohort).
Ethical approval was granted by NRES Committee 
Yorkshire & The Humber-Bradford Leeds (REC ref 13/
YH/0016). The trial was registered with the International 
Standard Randomised Controlled Trial Register (ISRCTN 
reference 82288852). Further trial details are provided else-
where [20, 25].
2.2  Economic Evaluation
The economic evaluation time horizon was 16 months. We 
did not model the intervention costs/consequences beyond 
the trial period, mainly due to lack of evidence for sustained 
effectiveness [4]. The evaluation followed the National Insti-
tute for Health and Care Excellence (NICE) reference case 
[26]. The primary end-point was cost per quality-adjusted 
life-year (QALY) gained at 16 months from the perspective 
of the health and personal social services provider. We also 
conducted a cost-effectiveness analysis presenting cost per 
unit change in CMAI.
2.3  Costs
DCM costs consisted of: (1) delivery and receipt of DCM 
training; and (2) DCM implementation. The DCM train-
ing required 4 days of staff time. Additional training costs 
included course fees, training materials, accommoda-
tion, meals, subsistence and travel. Implementation costs 
included mapper staff time and expert mapper involvement 
(cycle one). It was assumed (subsequently supported by the 
process evaluation) that additional time was not required 
for care-home staff to attend DCM briefing and feedback 
sessions, but that these were arranged at handover. We did 
not cost activities initiated as a result of the DCM process 
as it was assumed existing staff conducted these in existing 
sessions. The primary analysis assumed that the intervention 
was delivered as per protocol with all cycles implemented 
and costed. A sensitivity analysis only costed partially and 
fully implemented cycles.
Resident healthcare resource use in the previous 3 months 
was collected at 6 and 16 months by the researchers using 
care-home records. Simple linear extrapolation was used 
to handle coverage gaps in time due to the 3-month recall 
period (i.e. resource reported at 6 months was multiplied by 
2). This was also collected for a proportion of residents at 
baseline. Additional data on hospital visits/stays were also 
collected from administrative data and used as the primary 
source of secondary healthcare use. Medication use was cap-
tured at the same time points. Unit costs for resources were 
obtained from the PSSRU [27], eMIT national database [28] 
and NHS reference cost database [29] (see Supplementary 
Table 1). All prices are 2017 British Pounds (£).
2.4  Utility
Utility was measured at baseline, and at 6 and 16 months 
using the EQ-5D-5L [30], completed by residents, and the 
EQ-5D-5L-Proxy, completed by staff and relatives. The UK 
general population tariff [31] was used with a (− 5L to − 3L) 
mapping algorithm used as a sensitivity analysis [32]. Util-
ity values were also calculated using the DEMQOL-Proxy 
(DEMQOL-PROXY-U), completed by staff and relatives, 
and scored using the UK general population tariff [33].
The primary analysis was based on staff proxy EQ-5D-5L 
data as this represented the most complete response set. 
Further sensitivity analyses were based on the DEMQOL-
Proxy-U. EQ-5D-5L utility data is also presented employ-
ing (in order of priority) resident, relative proxies and staff 
proxies using the latter when the former was not available 
at all time-points.
2.5  Analysis
Total QALYs were calculated based on EQ-5D-5L and 
DEMQoL-Proxy-U utilities. If residents died, their util-
ity value was assumed to be zero with a linear transition 
from their previous health state. CMAI was calculated at 
each time point when residents were alive; those who died 
were excluded. Total costs combined intervention cost and 
resource use costs at 6 and 16 months. To capture the costs 
incurred prior to death, a daily cost was estimated based on 
previous resource consumption (at baseline or 6 months).
Incremental costs and QALYs (or CMAI) were estimated 
using a seemingly unrelated regression (SUR) approach 
accounting for the correlation between costs and outcomes. 
We implemented robust standard errors to account for the 
clustering at care-home level using the Stata nlsur package. 
The QALY model was adjusted for cluster size, baseline 
utility, age, gender and dementia severity (Clinical Dementia 
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Rating). Costs were adjusted for the same factors excluding 
baseline utility. We estimated incremental cost-effective-
ness ratios (ICERs) and used the NICE willingness-to-pay 
threshold of £20,000 (λ) to define cost-effectiveness [26]. 
We compared the CMAI ICERs to those estimated in previ-
ous research. A discount rate of 3.5% was used for costs and 
effects post 12 months.
Non-parametric bootstrapping was used to determine the 
level of sampling uncertainty around the ICER with results 
represented in a cost-effectiveness plane and cost-effective-
ness acceptability curve (CEAC) [34]. Our base-case analy-
ses took the intention-to-treat approach. Given the pragmatic 
nature of the trial and limited care-home compliance (only 
25.8% completing more than the one expert mapper sup-
ported DCM cycle), we also explored the impact of interven-
tion compliance on cost-effectiveness in sensitivity analyses.
2.6  Missing Data
We ran the resident-level analysis on complete cases (CCA) 
initially, requiring data on total QALYs and total costs. 
However, the primary analysis used data where missing 
values were imputed using multiple imputation (MI) based 
on an assumption that data were missing at random (MAR) 
[35]. The number of imputations (n = 48) reflected the ratio 
of missing:complete data. We used the predictive mean-
matching approach and included baseline values (cost or 
utility), age and binary variables denoting mortality in the 
imputation model. We also included study site to account 
for clustering within care homes. Rubin’s [36] rules were 
used to combine parameter estimates on the imputed data-
sets. Since the base-case analysis used proxy response data, 
there was some protection against informative missing data; 
however, we also conducted a sensitivity analysis to account 
for a missing not-at-random (MNAR) scenario. This used a 
Pattern Mixture Modelling approach with costs and QALYs 
systematically increased or decreased and the effect on prob-
ability of cost-effectiveness plotted. We used the approaches 
outlined in [35]: increasing costs in year 1 by 10–50% and 
subsequent years by 10% in DCM; doing this for DCM and 
control; reducing QALYs by 10–50% in year 1 and 10% in 
subsequent years in DCM; doing this for DCM and control.
2.7  Open‑Cohort Analysis
The open-cohort design meant that data from additional resi-
dents were available at 16 months. For the primary analysis, 
we only used data from residents consented into the trial at 
baseline (closed cohort; n = 726). An additional analysis was 
conducted that also incorporated data from the open cohort 
(n = 917). Where data were only available at 16 months, 
we imputed the total costs and QALYs for the whole trial 
period. This was implemented as a supplementary analysis 
to follow methods used in the primary statistical analysis. 
This approach necessarily assumes that survival is independ-
ent of the intervention and time spent in the care home and 
thus results should be considered illustrative only.
2.8  Sensitivity Analyses
Deterministic sensitivity analysis of the ICER tested 
the robustness of the results to changes in the analytical 
approach. We explored the impact on results of different 
approaches to costing, handling missing data and utility 
assessment.
3  Results
There were 389 residents in the complete case (where 
EQ-5D and resource use data are available at all time-points) 
and the sample described in Table 1. Supplementary Fig. 1 
outlines the data available for the economic evaluation. Data 
for 46% (337/726) had to be multiply imputed. A greater 
proportion of missingness was due to missing resource use 
than EQ-5D data (21% and 8% missing at month 6; 21% 
and 16% missing at month 16 for resource use and EQ-5D, 
respectively). In the complete case data, there were 19 clus-
ters in the control arm and 30 in the DCM arm. Mean (SD) 
number of residents per cluster were 14.11 (7.86) and 9.88 
(4.29), respectively. The intra-cluster correlation coefficients 
for costs, EQ-5D-5L QALYs and DEMQoL-U QALYs were 
0.02, 0.14 and 0.10, respectively. Supplementary Table 1 
includes information about cluster balance and informative 
clustering. There was some evidence of cluster imbalance 
(standardised difference > 10%) and of significant correla-
tion between costs and cluster size, hence we chose to adjust 
ICERs by the latter factor.
3.1  Costs
The costs of the DCM intervention and the assumptions 
behind this are described in Supplementary Table 2, and unit 
costs and descriptive statistics on resource use are included 
in Supplementary Tables 3 and 4, respectively. The total 
cost of the DCM intervention was estimated to be £421.07 
per resident (£9290.30 per care home on average). Control 
arm intervention costs were assumed to be zero. Unad-
justed resource use and total costs are presented in Table 2 
(UK £ sterling 2017 prices). Total costs were £3539.00 and 
£2059.58 on average per resident in the intervention and 
control arms, respectively. Non-parametric Mann–Whitney 
U tests suggest these costs were significantly different for the 
imputed and complete case (both p < 0.05) samples.
Primary-care costs were similar across arms while sec-
ondary-care costs were noticeably higher in the intervention 
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arm. The intervention arm included six high-cost individuals 
whose costs exceeded the maximum in the control arm, due 
to long hospital stays or one-to-one care; these individuals 
were excluded along with seven other high-cost individu-
als (generated in the imputation) in a sensitivity analysis. 
Baseline costs were similar across arms although slightly 
higher (mean) in the control group. However, there was a 
higher maximum cost in the intervention arm. Given this, 
and because baseline costs were only available on a sub-
sample, we only controlled for baseline costs as a sensitivity 
analysis.
3.2  Utility
Staff proxies provided the greatest proportion of utility 
data (n = 453; 62%), followed by relative proxies (n = 176; 
24%) and resident self-report (n = 168; 23%). Figure 1 
shows the utility values (with imputation) across different 
assessment strategies with the primary analysis based on 
data shown in Fig. 1a. There was baseline imbalance with 
the control arm having marginally higher baseline utility, 
which required adjustment. Mean EQ-5D scores declined 
during the trial over 16 months as may be expected given 
that deaths are coded as zero. The values from the 5L to 3L 
mapping were noticeably lower than the direct 5L valua-
tions. While the utility differential between arms appeared 
relatively trivial, this was larger in the combined patient/
carer/staff completion and DEMQoL-Proxy-U approaches.
Table 1  Sample characteristics 
at baseline
SD standard deviation, FAST Functional Assessment Staging Test
a Not mutually exclusive
Control group
N = 308 [% missing]
Intervention
N = 418 [% missing]
Total [% missing]
Age at randomisation, years [mean (SD)] 85.24 (7.37) [0%] 85.99 (7.83) [0%] 85.67 (7.64) [0%]
Male gender (%) 64 (20.78%) [0%] 126 (30.14%) [0%] 190 (26.17%) [0%]
Ethnic minority (%) 6 (1.95%) [0%] 18 (4.31%) [0%] 24 (3.31%) [0%]
Number of co-morbidities per resident 
[median (range)]
2 (0–10) [0%] 2 (0–14) [0%] 2 (0–14) [0%]
Selected co-morbiditiesa
 Anxiety [0% missing] 33 (10.71%) 21 (5.02%) 54 (7.44%)
 Depression [0% missing] 60 (19.48%) 52 (12.44%) 112 (15.43%)
 Psychosis [0% missing] 15 (4.87%) 24 (5.74%) 39 (5.37%)
 Sleep disturbance [0% missing] 6 (1.95%) 6 (1.44%) 12 (1.65%)
 Asthma [0% missing] 12 (3.90%) 20 (4.78%) 32 (4.41%)
FAST stage (out of completed scores) N = 306 [0.6%] N = 391 [6.5%] N = 697 [94.0%]
 4 (mild disease) 44 (14.38%) 57 (14.58%) 101 (14.49%)
 5 (moderate disease) 26 (8.50%) 48 (12.28%) 74 (10.62%)
 6 (moderately-severe disease) 166 (54.25%) 214 (54.73%) 380 (54.52%)
 7 (severe disease) 70 (22.88%) 72 (18.41%) 142 (20.37%)
Table 2  Intervention and resource use costs
For the base-case analysis group (the closed cohort, with staff-completed EQ-5D 5L data, discounted costs and after imputation). These values 
are unadjusted to reflect the true range of costs
SE standard error, CI confidence interval, Min minimum, Max maximum
Costs (£) Intervention (N = 418) Control (N = 308)
Mean SE (CIs) Min Max Mean SE (CIs) Min Max
Intervention cost £421 N/A N/A N/A £0 N/A N/A N/A
Primary-care costs £1522 £129.42 (£1256.86–£1787.78) £0 £19,560 £1568 £169.86 (£1208.03–£1928.24) £0 £8545
Secondary-care costs £1547 £338.55 (£851.83–£2242.84) £0 £67,347 £437 £140.62 (£138.73–£735.19) £0 £14,220
Medication costs £46 £4.73 (£36.70–£56.10) £0 £405 £54 £7.94 (£36.85–£70.49) £0 £459
Total cost £3539 £396.53 (£2724.73–£4352.98) £421 £73,944 £2060 £229.95 (£1571.93–£2547.24) £1 £18,032
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3.3  Cost‑effectiveness
The ICERs for the base-case and sensitivity analyses are 
given in Table 3A, B, respectively. In the base-case cost-
utility analysis (closed cohort, staff proxy EQ-5D-5L with 
multiple imputation), intervention was more costly (by 
£1479) and more effective (by 0.024 QALYs) than control. 
This yielded an adjusted ICER of £64,380 per QALY, well 
above the £20,000 NICE threshold, indicating that DCM 
is not cost-effective versus control. Figures 2 and 3 are the 
cost-effectiveness plane and the CEAC, respectively, for the 
base-case analysis. A majority of the simulations lie above 
the willingness-to-pay threshold, suggesting that DCM is 
unlikely to be cost-effective versus control. The CEAC indi-
cates that, where λ = £20,000, there is a very low probability 
(p = 0.13) that DCM will be cost-effective.
The complete-case analysis (full cost and utility data) 
yielded similar costs to the imputed sample but higher 
incremental QALYs for the intervention. With the excep-
tion of the analyses that excluded high-cost outliers (dis-
cussed below) and restricting the sample based on compli-
ance (at least two cycles of DCM completed), the ICERs 
from sensitivity analyses also exceeded £20,000. The sen-
sitivity analyses tended to show DCM having an incre-
mental QALY benefit (ranging from 0.24 to 0.61) but with 
higher costs (ranging from £364 to £1774) than control. 
The open-cohort analysis yielded lower incremental costs 
and higher incremental benefits for the intervention than 
the base case but an ICER (£46,556) still above £20,000.
In sensitivity analyses excluding high-cost outliers 
in the intervention arm (n = 6), incremental costs were 
reduced dramatically and the ICER was reduced but was 
still above the cost-effectiveness threshold (£41,905/
QALY) in the base case. However, the ICER fell below 
the threshold (£16,041/QALY) in the complete-case sce-
nario. The ICER also decreased with greater intervention 
compliance (≥ 1 cycles received = £37,289; ≥ 2 cycles 
received = £13,081). Analysis adjusting for baseline costs 
yielded reduced ICERs but were based on a much smaller 
sample (n = 123) and cannot be considered robust. The 
analysis exploring the assumption of missing at random 
in the multiple imputation is shown in Supplementary 
Fig. 2. We can see that systematic increases in the cost or 
decreases in the QALYs of those with missing data do not 
dramatically change the probability that DCM would be 
cost-effective and it never exceeds 0.25.
Cost-effectiveness analyses based on improvement in 
CMAI indicated that while the intervention was more 
costly, it was also more effective in reducing agitation. 
Incremental cost-per-unit improvement in CMAI was £272 
and £76 for intervention versus control for the imputed and 
complete case samples, respectively.
Fig. 1  Utility over time. Deaths coded as zero; c uses complete case data and a, b and d use imputed data; 3L indicates EQ-5D-3L
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4  Discussion
We conducted one of the most comprehensive economic 
evaluations of a non-pharmacological intervention to pre-
vent and support behavioural symptoms in dementia. The 
base-case analysis yielded an ICER of £64,380 per QALY, 
indicating that DCM in this context would not be an effi-
cient use of health/social service resources.
There are no other cost-utility studies that permit a 
direct comparison. We estimated the cost of delivering 
DCM to be £421.07 per person over the trial period. This 
is higher than estimates presented elsewhere (£119.06 
and £140.01 for two Australian studies [4] [both inflated 
from 2011 £GBP] and £2160 per care home for a Dutch 
study [37] [converted/inflated from 2013 $US]), although 
this may partially be explained by costing assumptions 
relating to the number of cycles and length of follow-up. 
These figures are also likely to be sensitive to the resi-
dent denominator (how many people the costs are spread 
across). However, reductions in the cost of DCM (based on 
spreading training costs over additional years or only cost-
ing implemented cycles) did not impact the decision. Our 
base-case estimate of the cost of CMAI unit improvement 
(£272) was higher than previous estimates (£26.77 [18] 
[converted/inflated from 2008 $Aus]; £6.61–£68.35 [4] 
[inflated from 2011 £GBP]), perhaps for the reasons given 
above. Costs of resource use were substantially higher in 
the intervention arm than the control. This was driven by 
higher secondary-care costs resulting from (n = 6) high-
cost individuals in the intervention arm. A strength of this 
study was the range of utility assessment strategies used 
but, while these led to absolute QALY differences, the 
between-arm utility differences were small.
The sensitivity analyses were consistent in finding the 
intervention to be more costly and effective than control. 
Most analyses yielded ICERs well above the £20,000 thresh-
old; a complete case analysis excluding high-cost outliers 
(£16,041/QALY), and analysis including only those care 
homes completing two or more DCM cycles (£13,081/
QALY) being exceptions. Lower ICERs observed for analy-
ses restricting the sample, e.g. requiring baseline costs for 
adjustment or including compliant care homes, were pos-
sibly due to the coincidental omission of cost outliers.
4.1  Methodological Challenges and Future 
Research
Economic evaluations in dementia and care-home settings 
share the same challenges as other primary research con-
ducted in these contexts relating to data completeness and 
quality. Specific issues encountered here related to high loss 
to follow-up of residents and their proxies, low intervention 
compliance, the validity of quality-of-life data and accurate 
cost attribution in a group who incur higher than average 
resource use. Furthermore, choice of time horizon and per-
spective was not straightforward. A number of assumptions 
and approaches were adopted to deal with these issues.
We chose a narrow cost perspective (health and personal 
social services) in our analyses, as recommended by NICE. 
In theory, DCM could have institutional benefits that may 
result in cost savings (for example, via reduced staff turno-
ver); however this was not borne out in our trial results and 
thus not considered. Future evaluations in this population 
could explore additional perspectives including that of the 
care home itself, especially where they commission inter-
ventions directly. However, this will be complicated by the 
fact that many homes have combined healthcare-funded and 
self-funded residents, still receive funding when residents 
Fig. 2  Cost-effectiveness plane: intervention versus control. 
DCM + UC dementia care mapping plus usual care, UC usual care
Fig. 3  Cost-effectiveness acceptability curve. DCM dementia care 
mapping
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are in secondary care and may receive quality improvement 
incentives from the healthcare system.
We limited our analysis to the trial period, electing not 
to model costs and benefits forward over time. There does 
appear to be a small QALY benefit for DCM over control; 
if this were extrapolated forward, assuming the intervention 
costs are sunk, then cost-effectiveness metrics for DCM may 
improve in line with the time horizon. This is especially true 
if benefits are extended to residents (present and future) not 
included in the trial. However, such an approach would be 
highly speculative and there is no evidence that any DCM 
effects would be sustained, either for individuals or institu-
tionally. Furthermore, any future effect will be attenuated 
by the high staff turnover that often occurs in care homes, 
impacting on DCM delivery. Any modelling forward of 
benefits in this setting would have to justify the duration 
of effect both for the individual and the institution, justify 
the denominator population (for sunk costs) and potentially 
factor in additional costs to train new staff.
Poor intervention implementation was a significant chal-
lenge in the current trial. While our primary analysis was 
based on intention to treat, we explored the impact of com-
pliance in the sensitivity analyses. The Complier Average 
Causal Effect (CACE) is an alternative approach to dealing 
with non-compliance that is beginning to see application in 
economic evaluations [38]; however, we did not believe it 
was relevant in our context as non-compliance was at the 
care-home level only and was observable.
Missing data (around 45% at 16 months) in the trial was 
substantial and handled in a standard way, relying on mul-
tiple imputation. Due to high losses to follow-up, the trial 
design was changed to an open cohort study, recruiting addi-
tional residents at final follow-up to maintain power in the 
statistical analysis for the primary end-point. However, since 
economic evaluations analyse the stream of costs and ben-
efits across the trial period, this innovation led to a greater 
reliance on imputation and was consequently considered a 
supplementary analysis only. Additional research is needed 
to help understand whether open-cohort designs can have a 
role in economic evaluations. We used care-home records 
as a source for secondary-care use and would recommend 
this approach (or other administrative data capture such as 
NHS Digital) to minimise the impact of loss to follow-up 
and reduce missing data.
Previous research has highlighted the challenges in qual-
ity-of-life assessment in this group [39]. These challenges 
relate to the level of missing data, validity of either self- 
or proxy- reports, and the ability of available measures to 
capture relevant disease and intervention impacts. We used 
several approaches to capture utility to allow an assessment 
of which was most appropriate and practical. The utility 
capture strategy based on the DEMQoL-Proxy-U yielded 
the greatest incremental QALYs for DCM and around a 
£24,000 reduction in the ICER compared to the staff EQ-
5D-5L method. It is not clear why this is the case: it may be 
evidence of greater sensitivity of the disease-specific meas-
ure but the absolute differences versus the EQ-5D are very 
small. Equally, it may relate to the sample reporting on this 
measure. Research suggests individuals with mild cognitive 
impairment can provide valid self-reports and for those that 
cannot, proxy reports may be used [39]. However, research 
is needed to identify the threshold for utility measure self-
completion and to test methods of combining self-complete 
and proxy data, which may include adjustment of values or 
mapping.
The economic evaluation results were heavily influenced 
by high-cost outliers. When we examined the reason for hos-
pital admission for the cost outliers, it was not possible to 
rule out attribution to the receipt of DCM. For example, it 
is conceivable (although, unlikely) that DCM was associ-
ated with the implementation of more activities and this may 
have led to adverse events such as falls. Given this, there was 
no reasonable justification for removing these individuals 
from the main analyses. While some consideration has been 
given to the impact of high-cost individuals [40], further 
research is needed on this topic. Additional information on 
the cause of secondary-care resource use may be useful since 
this often drives overall costs. However, a systematic and 
transparent method of judging whether that use was related 
to intervention receipt or not, for example, via an independ-
ent clinical assessment may also be needed. It is possible 
that such an assessment could sit within a quantitative pro-
cess evaluation framework and may inform additional sen-
sitivity analyses.
5  Conclusion
We did not find DCM, as delivered in this study, to be cost-
effective versus control and conclude that future research 
should investigate the value for money of alternative strate-
gies to help prevent and support behavioural symptoms in 
people living with dementia in care homes.
The DCM-EPIC trial setting and data posed a number of 
challenges for the economic evaluation. The use of admin-
istrative data and running several concurrent data capture 
strategies, followed by extensive sensitivity analyses using 
these data sources, may help mitigate the challenges and 
reduce uncertainty around the results. Additional research 
on innovative trial designs and statistical approaches to deal-
ing with issues of compliance is required, as is research to 
optimise utility assessment in this population and to identify 
methods of dealing with cost outliers.
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